Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Klebsiella pneumoniae | 5 | 2019 | 658 | 2.01 | Why? |
| beta-Lactamases | 6 | 2019 | 759 | 1.62 | Why? |
| Klebsiella Infections | 3 | 2018 | 466 | 1.48 | Why? |
| HIV-1 | 14 | 2019 | 3365 | 1.40 | Why? |
| Plasmids | 3 | 2018 | 840 | 1.13 | Why? |
| Azabicyclo Compounds | 2 | 2019 | 91 | 0.87 | Why? |
| Ceftazidime | 2 | 2019 | 134 | 0.85 | Why? |
| Nevirapine | 2 | 2017 | 57 | 0.81 | Why? |
| HIV Infections | 16 | 2021 | 11620 | 0.80 | Why? |
| Boronic Acids | 1 | 2019 | 30 | 0.79 | Why? |
| Kluyvera | 1 | 2018 | 5 | 0.79 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2019 | 214 | 0.78 | Why? |
| Anti-HIV Agents | 7 | 2017 | 2209 | 0.76 | Why? |
| Cyclohexanes | 2 | 2017 | 43 | 0.68 | Why? |
| Proviruses | 1 | 2017 | 82 | 0.65 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.65 | Why? |
| Tears | 1 | 2020 | 400 | 0.64 | Why? |
| Bacterial Proteins | 4 | 2019 | 1318 | 0.61 | Why? |
| Conjunctiva | 1 | 2020 | 620 | 0.55 | Why? |
| Triazoles | 2 | 2017 | 440 | 0.50 | Why? |
| HIV Fusion Inhibitors | 1 | 2013 | 80 | 0.49 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.46 | Why? |
| Receptors, CCR5 | 1 | 2013 | 186 | 0.45 | Why? |
| Drug Resistance, Viral | 3 | 2013 | 1083 | 0.42 | Why? |
| Rosuvastatin Calcium | 3 | 2018 | 89 | 0.39 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.37 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.36 | Why? |
| Bone Diseases, Metabolic | 1 | 2008 | 64 | 0.35 | Why? |
| DNA, Viral | 4 | 2019 | 2521 | 0.33 | Why? |
| Viral Load | 9 | 2020 | 15850 | 0.32 | Why? |
| Renal Insufficiency, Chronic | 2 | 2018 | 2654 | 0.30 | Why? |
| Rectum | 2 | 2019 | 495 | 0.30 | Why? |
| Anticholesteremic Agents | 2 | 2018 | 186 | 0.30 | Why? |
| Hyperlipidemias | 2 | 2018 | 290 | 0.29 | Why? |
| Antiretroviral Therapy, Highly Active | 4 | 2017 | 952 | 0.28 | Why? |
| Drug Synergism | 2 | 2019 | 833 | 0.28 | Why? |
| HIV Reverse Transcriptase | 1 | 2004 | 104 | 0.26 | Why? |
| HIV Protease | 1 | 2004 | 86 | 0.26 | Why? |
| Enterobacteriaceae Infections | 2 | 2019 | 529 | 0.25 | Why? |
| Osteoporosis | 1 | 2008 | 410 | 0.24 | Why? |
| Amino Acid Substitution | 2 | 2005 | 1706 | 0.20 | Why? |
| Mycobacterium tuberculosis | 2 | 2019 | 1164 | 0.19 | Why? |
| Sequence Analysis, DNA | 3 | 2017 | 2830 | 0.19 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.19 | Why? |
| Hepatitis B Core Antigens | 1 | 2019 | 76 | 0.19 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2016 | 5164 | 0.19 | Why? |
| Hepatitis B e Antigens | 1 | 2019 | 99 | 0.18 | Why? |
| Diagnostic Tests, Routine | 3 | 2019 | 2643 | 0.18 | Why? |
| Antibiotics, Antitubercular | 1 | 2018 | 65 | 0.18 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2019 | 449 | 0.17 | Why? |
| Darunavir | 2 | 2017 | 477 | 0.17 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.17 | Why? |
| Bacteriological Techniques | 1 | 2019 | 239 | 0.17 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.16 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.16 | Why? |
| Rifampin | 1 | 2018 | 276 | 0.16 | Why? |
| Chikungunya virus | 1 | 2019 | 339 | 0.16 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.15 | Why? |
| Chikungunya Fever | 1 | 2019 | 345 | 0.15 | Why? |
| Dysbiosis | 1 | 2021 | 685 | 0.14 | Why? |
| Genome, Bacterial | 1 | 2018 | 446 | 0.14 | Why? |
| CD4 Lymphocyte Count | 2 | 2017 | 1517 | 0.14 | Why? |
| Vitamin D Deficiency | 2 | 2019 | 1782 | 0.14 | Why? |
| Nuclear Proteins | 1 | 2017 | 321 | 0.14 | Why? |
| Candidemia | 1 | 2018 | 353 | 0.13 | Why? |
| Drug Substitution | 2 | 2017 | 385 | 0.13 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| CCR5 Receptor Antagonists | 1 | 2013 | 66 | 0.13 | Why? |
| Oligopeptides | 1 | 2016 | 576 | 0.12 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.12 | Why? |
| Hepatitis B, Chronic | 1 | 2019 | 616 | 0.11 | Why? |
| Humans | 40 | 2021 | 930598 | 0.11 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.11 | Why? |
| Italy | 7 | 2021 | 38444 | 0.11 | Why? |
| Infant, Premature | 1 | 2016 | 883 | 0.11 | Why? |
| Sputum | 1 | 2019 | 1720 | 0.11 | Why? |
| HTLV-I Antibodies | 1 | 1989 | 2 | 0.11 | Why? |
| Base Sequence | 1 | 2018 | 3581 | 0.10 | Why? |
| Drug Therapy, Combination | 3 | 2020 | 7268 | 0.10 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.10 | Why? |
| Human T-lymphotropic virus 1 | 1 | 1989 | 52 | 0.10 | Why? |
| HTLV-I Infections | 1 | 1989 | 54 | 0.10 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 877 | 0.10 | Why? |
| Tuberculosis, Pulmonary | 1 | 2019 | 1171 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Interferons | 1 | 2020 | 2885 | 0.09 | Why? |
| Gastrointestinal Microbiome | 1 | 2021 | 1961 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.09 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.08 | Why? |
| Virus Replication | 3 | 2018 | 14331 | 0.08 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.08 | Why? |
| Female | 20 | 2021 | 380317 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.08 | Why? |
| Phosphoproteins | 1 | 2017 | 4346 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.08 | Why? |
| Virus Integration | 1 | 2006 | 96 | 0.08 | Why? |
| Male | 19 | 2021 | 367725 | 0.07 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.07 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Viral Tropism | 1 | 2013 | 1329 | 0.07 | Why? |
| Adult | 16 | 2021 | 244371 | 0.07 | Why? |
| Interferon Type I | 1 | 2018 | 2789 | 0.07 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.07 | Why? |
| Virus Latency | 1 | 2006 | 251 | 0.07 | Why? |
| Treatment Outcome | 5 | 2018 | 51732 | 0.06 | Why? |
| Ritonavir | 4 | 2020 | 4212 | 0.06 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.06 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.06 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.06 | Why? |
| RNA, Viral | 3 | 2017 | 32276 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2013 | 17020 | 0.05 | Why? |
| Genotype | 1 | 2013 | 4697 | 0.05 | Why? |
| Reagent Kits, Diagnostic | 2 | 2018 | 2149 | 0.05 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.05 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Viremia | 2 | 2017 | 1020 | 0.05 | Why? |
| Gene Products, tat | 1 | 1998 | 7 | 0.05 | Why? |
| Mutation, Missense | 1 | 2005 | 863 | 0.05 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.05 | Why? |
| Jurkat Cells | 1 | 1998 | 273 | 0.05 | Why? |
| RNA | 1 | 2006 | 1278 | 0.04 | Why? |
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 4 | 0.04 | Why? |
| Young Adult | 4 | 2019 | 93724 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2021 | 793 | 0.04 | Why? |
| Sensitivity and Specificity | 4 | 2019 | 22971 | 0.04 | Why? |
| Interferon beta-1a | 1 | 2020 | 316 | 0.04 | Why? |
| Imipenem | 1 | 2017 | 57 | 0.04 | Why? |
| Thienamycins | 1 | 2017 | 72 | 0.04 | Why? |
| Chromatography, Affinity | 1 | 2019 | 310 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 96 | 0.04 | Why? |
| Serum | 1 | 2019 | 294 | 0.04 | Why? |
| Hepatitis Antibodies | 1 | 2017 | 100 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2019 | 305 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| beta-Lactamase Inhibitors | 1 | 2017 | 104 | 0.04 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.04 | Why? |
| Mosquito Vectors | 1 | 2019 | 351 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2019 | 536 | 0.04 | Why? |
| Lamivudine | 1 | 2017 | 210 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.04 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.04 | Why? |
| Atazanavir Sulfate | 1 | 2017 | 213 | 0.04 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.04 | Why? |
| Cephalosporins | 1 | 2017 | 250 | 0.04 | Why? |
| Fatty Acids, Omega-3 | 1 | 2018 | 306 | 0.03 | Why? |
| Aged | 8 | 2021 | 215776 | 0.03 | Why? |
| Pregnancy | 1 | 2016 | 23879 | 0.03 | Why? |
| HIV Protease Inhibitors | 1 | 2017 | 434 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2017 | 499 | 0.03 | Why? |
| Geography | 1 | 2019 | 1801 | 0.03 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.03 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.03 | Why? |
| Cohort Studies | 3 | 2017 | 36005 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2019 | 27595 | 0.03 | Why? |
| Acute Disease | 1 | 2004 | 6029 | 0.03 | Why? |
| Microbiota | 1 | 2021 | 1240 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2019 | 1783 | 0.03 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.03 | Why? |
| Homosexuality, Male | 1 | 2019 | 1158 | 0.03 | Why? |
| Workflow | 1 | 2019 | 2373 | 0.02 | Why? |
| Population | 1 | 1989 | 114 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.02 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2019 | 1019 | 0.02 | Why? |
| Chronic Disease | 1 | 2004 | 5139 | 0.02 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.02 | Why? |
| Membrane Glycoproteins | 1 | 2017 | 2273 | 0.02 | Why? |
| Software | 1 | 2019 | 2501 | 0.02 | Why? |
| Child | 3 | 2020 | 70012 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.02 | Why? |
| Indonesia | 1 | 1989 | 1022 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2019 | 88759 | 0.02 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Genes, tat | 1 | 1998 | 1 | 0.01 | Why? |
| Viral Proteins | 1 | 1998 | 7370 | 0.01 | Why? |
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 24 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Transfection | 1 | 1998 | 864 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 1989 | 7868 | 0.01 | Why? |
| Flow Cytometry | 1 | 1998 | 2393 | 0.01 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |
Re's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(208)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(116)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_